🇺🇸 FDA

Intelligence Platform

Patents

Browse 252 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10183942

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10172834

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amin

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130642

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10123984

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10106503

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10100013

Crystalline freebase forms of a biphenyl compound

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10100049

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10100021

Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydr

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10081626

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072026

Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin

Theravance Biopharma R&D IP, LLC · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10053417

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10034870

4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Theravance Biopharma R&D IP, LLC · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10028960

Pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10005740

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9981999

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9975877

Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

Theravance Biopharma R&D IP, LLC · Granted Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9949963

Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

Theravance Biopharma R&D IP, LLC · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9926272

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884807

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9873685

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9872855

(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amin

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9873696

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9873692

Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868698

(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methy

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted